Literature DB >> 19523354

Pituitary tumors.

Nestoras Mathioudakis1, Roberto Salvatori.   

Abstract

Pituitary adenomas are the most common intrasellar tumors. With the exception of prolactinomas, first-line treatment is almost always surgical. Prolactinomas are usually treated with dopamine agonists such as cabergoline or bromocriptine. Somatostatin analogues, such as octreotide and lanreotide, can be adjunctive to surgical therapy in acromegaly, although they can be used as primary therapy in selected cases. Pegvisomant, a growth hormone receptor antagonist, is reserved for acromegalic patients who are resistant to treatment with somatostatin analogues. No effective medical therapy is available for adenomas that secrete adrenocorticotropic hormone, and occasionally bilateral adrenalectomy is required to resolve severe hypercortisolemia. Radiation therapy (fractionated or radiosurgery) can be used for residual or recurrent pituitary tumors. Asymptomatic, nonfunctioning pituitary adenomas may be followed without any intervention, but surgery is typically indicated if there are symptoms of mass effect on the optic chiasm or endocrine dysfunction. In the hands of an experienced pituitary neurosurgeon, the prognosis for endocrinologic recovery and visual improvement is good.

Entities:  

Year:  2009        PMID: 19523354     DOI: 10.1007/s11940-009-0032-6

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  53 in total

1.  The cabergoline-resistant prolactinoma patient: new challenges.

Authors:  Mark E Molitch
Journal:  J Clin Endocrinol Metab       Date:  2008-12       Impact factor: 5.958

2.  The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery.

Authors:  Rosario Pivonello; Maria Cristina De Martino; Paolo Cappabianca; Monica De Leo; Antongiulio Faggiano; Gaetano Lombardi; Leo J Hofland; Steven W J Lamberts; Annamaria Colao
Journal:  J Clin Endocrinol Metab       Date:  2008-10-28       Impact factor: 5.958

3.  Cabergoline and the risk of valvular lesions in endocrine disease.

Authors:  Patrizio Lancellotti; Elena Livadariu; Muriel Markov; Adrian F Daly; Maria-Cristina Burlacu; Daniela Betea; Luc Pierard; Albert Beckers
Journal:  Eur J Endocrinol       Date:  2008-05-02       Impact factor: 6.664

4.  Effects of lanreotide Autogel on growth hormone, insulinlike growth factor 1, and tumor size in acromegaly: a 1-year prospective multicenter study.

Authors:  Roberto Attanasio; Roberto Lanzi; Marco Losa; Ferdinando Valentini; Franco Grimaldi; Ernesto De Menis; Maria Vittoria Davì; Claudia Battista; Roberto Castello; Nadia Cremonini; Paola Razzore; Francesca Rosato; Marcella Montini; Renato Cozzi
Journal:  Endocr Pract       Date:  2008-10       Impact factor: 3.443

5.  The endonasal microscopic approach for pituitary adenomas and other parasellar tumors: a 10-year experience.

Authors:  Nasrin Fatemi; Joshua R Dusick; Manoel A de Paiva Neto; Daniel F Kelly
Journal:  Neurosurgery       Date:  2008-10       Impact factor: 4.654

Review 6.  Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry.

Authors:  Wolfgang Saeger; Dieter K Lüdecke; Michael Buchfelder; Rudolf Fahlbusch; Hans-Jürgen Quabbe; Stephan Petersenn
Journal:  Eur J Endocrinol       Date:  2007-02       Impact factor: 6.664

Review 7.  Practical pituitary pathology: what does the pathologist need to know?

Authors:  Sylvia L Asa
Journal:  Arch Pathol Lab Med       Date:  2008-08       Impact factor: 5.534

8.  Treatment with low doses of cabergoline is not associated with increased prevalence of cardiac valve regurgitation in patients with hyperprolactinaemia.

Authors:  F Bogazzi; S Buralli; L Manetti; V Raffaelli; T Cigni; M Lombardi; F Boresi; S Taddei; A Salvetti; E Martino
Journal:  Int J Clin Pract       Date:  2008-05-06       Impact factor: 2.503

Review 9.  Surgery for Cushing's syndrome: an historical review and recent ten-year experience.

Authors:  John R Porterfield; Geoffrey B Thompson; William F Young; John T Chow; Raymond S Fryrear; Jon A van Heerden; David R Farley; John L D Atkinson; Fredric B Meyer; Charles F Abboud; Todd B Nippoldt; Neena Natt; Dana Erickson; Adrian Vella; Paul C Carpenter; Melanie Richards; J Aidan Carney; Dirk Larson; Cathy Schleck; Marilyn Churchward; Clive S Grant
Journal:  World J Surg       Date:  2008-05       Impact factor: 3.352

Review 10.  Nonfunctioning pituitary tumors and pituitary incidentalomas.

Authors:  Mark E Molitch
Journal:  Endocrinol Metab Clin North Am       Date:  2008-03       Impact factor: 4.741

View more
  3 in total

1.  Identification of Potential Biomarkers with Diagnostic Value in Pituitary Adenomas Using Prediction Analysis for Microarrays Method.

Authors:  Hu Peng; Yue Deng; Longhao Wang; Yin Cheng; Yaping Xu; Jianchun Liao; Hao Wu
Journal:  J Mol Neurosci       Date:  2019-07-06       Impact factor: 3.444

2.  Clinical features of sellar and suprasellar meningiomas.

Authors:  Ratchaneewan Kwancharoen; Ari M Blitz; Fabiana Tavares; Patrizio Caturegli; Gary L Gallia; Roberto Salvatori
Journal:  Pituitary       Date:  2014-08       Impact factor: 4.107

3.  A lifelong smoker with hypopituitarism: rethinking the hypothesis of a tumor in the hypophysis.

Authors:  Nestoras Mathioudakis; Alfredo Quinones-Hinojosa; Roberto Salvatori; Shehzad Basaria
Journal:  Case Rep Med       Date:  2012-04-22
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.